The role of age on dose-limiting toxicities in Phase i dose-escalation trials

Clinical Cancer Research

Volumn 20, Issue 18, 2014, Pages 4768-4775

  Schwandt, A ^a   Harris, P J ^b   Hunsberger, S ^b   Deleporte, A ^c   Smith, G L ^b   Vulih, D ^d   Anderson, B D ^d   Ivy, S P ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JULES BORDET INSTITUTE   (Belgium)

^d Theradex   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGE; AGED; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; META ANALYSIS; NEOPLASMS; PHASE 1 CLINICAL TRIAL (TOPIC); RETROSPECTIVE STUDY; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84907916513     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0866     Document Type: Article

References (36)

1. Muss HB, Cohen HJ, Lichtman SM. Clinical research in the older cancer patient. HematolOncol Clin North Am 2000;14:283-91.
2. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancertreatment trials. N Engl J Med 1999;341:2061-7.
3. Basche M, Bar-on AE, Eckhardt SG, Balducci L, Persky M, Levin A, et al. Barriers to enrollment of elderly adults in early-phase cancer clinical trials. J Oncol Pract 2008;4:162-8.
4. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383-9.
5. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: Race-, sex-, and age-based disparities.JAMA2004;291:2720-6.
6. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US food and drug administration. J Clin Oncol 2004;22:4626-31.
7. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005;352:895-904.
8. Zafar SF, Heilbrun LK, Vishnu P, Jasti P, Venkatramanamoorthy R, Ding L, et al. Participation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experience. J Geriatr Oncol 2011;2:18-24.
9. Jardim DL, Hess KR, Lorusso P, Kurzrock R, Hong DS. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res 2014;20:281-8.
10. Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 2008;112:228-42.
11. Hurria A, Wong FL, Villaluna D, Bhatia S, Chung CT, Mortimer J, et al. Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers. J Clin Oncol 2008;26:5386-92.
12. KornblithAB,Kemeny M,Peterson BL,Wheeler J,Crawford J,Bartlett N, et al. Survey of oncologists' perceptions of barriers to accrual of older patientswith breast carcinomato clinical trials. Cancer 2002;95:989-96.
13. Kemeny MM, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003;21:2268-75.
14. Arkenau HT, Olmos D, Ang JE, de Bono J, Judson I, Kaye S. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 2008;98:1029-33.
15. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, Judson I, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 2009;27:2692-6.
16. Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, et al. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res 2012; 18:2922-9.
17. Arkenau HT, Olmos D, Ang JE, Barriuso J, Karavasilis V, Ashley S, et al. 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer 2008;44:1536-40.
18. Bachelot T, Ray-Coquard I, Catimel G, Ardiet C, Guastalla JP, Dumortier A, et al. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 2000; 11:151-6.
19. Gaddipati H, Fu P, Dowlati A. Phase I clinical trials in patients-80. J Geriatr Oncol 2011;2:142-6.
20. LoConte NK, Smith M, Alberti D, Bozeman J, Cleary JF, Setala AN, et al. Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy. Cancer Chemother Pharmacol 2010;65:775-80.
21. Agresti A, Booth JG, Hobart JP, Caffo B. Random-effects modeling of categorical response data. Sociol Methodol 2000;30:27-80.
22. Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 2010;16:1726-36.
23. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, et al. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clin Breast Cancer 2010;10:46-51.
24. Molife LR, Alam S, Olmos D, Puglisi M, Shah K, Fehrmann R, et al. Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. Ann Oncol 2012;23: 1968-73.
25. Hyman DM, Eaton AA, Gounder MM, Smith GL, Pamer EG, Hensley ML, et al. Nomogramto predict cycle-one serious drug-related toxicity in phase I oncology trials. J Clin Oncol 2014;32:519-26.
26. Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, et al. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol 2012;23:1963-7.
27. Owusu C, Koroukian SM, Schluchter M, Bakaki P, Berger NA. Screening older cancer patients for a Comprehensive Geriatric Assessment: a comparison of three instruments. J Geriatr Oncol 2011;2:121-9.
28. van der Biessen DA, Cranendonk MA, Schiavon G, van der Holt B, Wiemer EA, Eskens FA, et al. Evaluation of patient enrollment in oncology phase I clinical trials. Oncologist 2013;18:323-9.
29. Mohd Noor A, Sarker D, Vizor S, McLennan B, Hunter S, Suder A, et al. Effect of patient socioeconomic status on access to early-phase cancer trials. J Clin Oncol 2013;31:224-30.
30. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
31. Koroukian SM. Assessment and interpretation of comorbidity burden in older adults with cancer. J Am Geriatr Soc 2009;57 Suppl 2:S275-8.
32. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-27.
33. Prithviraj GK, Koroukian S, Margevicius S, Berger NA, Bagai R, Owusu C. Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. J Geriatr Oncol 2012;3:228-37.
34. Bowlin SJ, Xia F, Wang W, Robinson KD, Stanek EJ. Twelve-month frequency of drug-metabolizing enzyme and transporter-based drugdrug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clin Proc 2013;88: 139-48.
35. Mazzola P, Radhi S, Mirandola L, Annoni G, Jenkins M, Cobos E, et al. Aging, cancer, and cancer vaccines. Immun Ageing 2012;9:4.
36. Mohile SG, Fan L, Reeve E, Jean-Pierre P, Mustian K, Peppone L, et al. Association of cancer with geriatric syndromes in older Medicare beneficiaries. J Clin Oncol 2011;29:1458-64.